Bey Douglas LLC Sells 107 Shares of Stryker Co. (NYSE:SYK)

Bey Douglas LLC lessened its holdings in Stryker Co. (NYSE:SYK) by 0.8% during the fourth quarter, HoldingsChannel reports. The fund owned 14,119 shares of the medical technology company’s stock after selling 107 shares during the quarter. Stryker accounts for about 4.4% of Bey Douglas LLC’s investment portfolio, making the stock its 11th biggest holding. Bey Douglas LLC’s holdings in Stryker were worth $5,083,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in SYK. Asset Management One Co. Ltd. lifted its stake in Stryker by 0.8% during the 4th quarter. Asset Management One Co. Ltd. now owns 133,843 shares of the medical technology company’s stock valued at $49,135,000 after acquiring an additional 1,106 shares in the last quarter. Aljian Capital Management LLC lifted its position in shares of Stryker by 7.0% during the fourth quarter. Aljian Capital Management LLC now owns 13,493 shares of the medical technology company’s stock valued at $4,858,000 after purchasing an additional 888 shares in the last quarter. Avestar Capital LLC boosted its holdings in Stryker by 8.7% during the fourth quarter. Avestar Capital LLC now owns 3,205 shares of the medical technology company’s stock worth $1,154,000 after purchasing an additional 257 shares during the last quarter. One Plus One Wealth Management LLC bought a new stake in Stryker in the 4th quarter worth about $200,000. Finally, HMS Capital Management LLC increased its stake in Stryker by 0.8% in the 4th quarter. HMS Capital Management LLC now owns 4,668 shares of the medical technology company’s stock valued at $1,681,000 after buying an additional 37 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.90% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on SYK. Wells Fargo & Company boosted their target price on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Truist Financial boosted their price objective on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday, January 30th. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, January 30th. Royal Bank of Canada boosted their price target on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Finally, Stifel Nicolaus raised their price objective on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $420.68.

Stryker Trading Up 0.7 %

Shares of SYK stock opened at $388.28 on Friday. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The company’s fifty day simple moving average is $377.19 and its two-hundred day simple moving average is $366.15. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The stock has a market capitalization of $148.02 billion, a price-to-earnings ratio of 50.04, a PEG ratio of 2.98 and a beta of 0.96.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the business posted $3.46 EPS. As a group, analysts anticipate that Stryker Co. will post 13.49 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.87%. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.